Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2014 1
2015 1
2016 1
2017 2
2020 1
2021 6
2022 7
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study.
Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K. Atsukawa M, et al. Among authors: tateyama m. Hepatol Int. 2023 Feb;17(1):139-149. doi: 10.1007/s12072-022-10456-y. Epub 2022 Dec 7. Hepatol Int. 2023. PMID: 36477691 Clinical Trial.
[A case of ectopic hepatocellular carcinoma].
Fukuda S, Yano K, Ohata K, Nonaka K, Tateyama M, Taura N, Komori A, Abiru S, Yatsuhashi H, Ito M, Fujioka H, Ishibashi H. Fukuda S, et al. Among authors: tateyama m. Nihon Shokakibyo Gakkai Zasshi. 2009 Dec;106(12):1770-7. Nihon Shokakibyo Gakkai Zasshi. 2009. PMID: 19966520 Review. Japanese.
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
Nagura Y, Matsuura K, Iio E, Fujita K, Inoue T, Matsumoto A, Tanaka E, Nishiguchi S, Kang JH, Matsui T, Enomoto M, Ikeda H, Watanabe T, Okuse C, Tsuge M, Atsukawa M, Tateyama M, Kataoka H, Tanaka Y. Nagura Y, et al. Among authors: tateyama m. PLoS One. 2022 Feb 14;17(2):e0263844. doi: 10.1371/journal.pone.0263844. eCollection 2022. PLoS One. 2022. PMID: 35157730 Free PMC article.
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y. Narahara S, et al. Among authors: tateyama m. Hepatol Commun. 2022 May;6(5):1198-1212. doi: 10.1002/hep4.1872. Epub 2021 Nov 27. Hepatol Commun. 2022. PMID: 34837478 Free PMC article.
A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.
Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y. Kawaratani H, et al. Among authors: tateyama m. Liver Int. 2021 Dec;41(12):2944-2953. doi: 10.1111/liv.15022. Epub 2021 Aug 8. Liver Int. 2021. PMID: 34309184
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: tateyama m. Hepatol Res. 2022 Jan;52(1):105-119. doi: 10.1111/hepr.13720. Epub 2021 Oct 22. Hepatol Res. 2022. PMID: 34626450
24 results